

## COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY 13497

### VII. NOTICE OF PUBLIC HEARING

The Commissioner concludes that, to permit maximum public participation in the development of labeling requirements for oral hypoglycemic drug products, a public hearing shall be held to provide an opportunity for interested persons to present data, information, and views on the proposed labeling. This public hearing is ordered pursuant to § 2.400(a) (21 CFR 2.400(a)) and shall be conducted in accordance with the procedures established in Subpart E of Part 2 of the regulations. The Commissioner has designated J. Richard Crout, M.D., Director, Bureau of Drugs, to be the presiding officer at such hearing, to be held August 20, 1975, beginning at 9 a.m. in Conference Rm. E, Parklawn Bldg., 5600 Fishers Lane, Rockville, MD 20852.

Interested persons who wish to make an oral presentation at the hearing shall file a written notice of appearance with the Hearing Clerk, Food and Drug Administration, Rm. 4-65, 5600 Fishers Lane, Rockville, MD 20852 by close of business August 6, 1975. The